Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) FCF Margin (2020 - 2022)

Elicio Therapeutics filings provide 3 years of FCF Margin readings, the most recent being 854.06% for Q2 2022.

  • On a quarterly basis, FCF Margin rose 284943.0% to 854.06% in Q2 2022 year-over-year; TTM through Mar 2023 was 2348.55%, a 215500.0% decrease, with the full-year FY2022 number at 992.31%, down 80091.0% from a year prior.
  • FCF Margin hit 854.06% in Q2 2022 for Elicio Therapeutics, up from 949.82% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 854.06% in Q2 2022 to a low of 3394.07% in Q1 2021.
  • Median FCF Margin over the past 3 years was 1045.21% (2021), compared with a mean of 1324.17%.
  • Biggest five-year swings in FCF Margin: tumbled -23762bps in 2021 and later surged 284943bps in 2022.
  • Elicio Therapeutics' FCF Margin stood at 924.01% in 2020, then soared by 94bps to 55.78% in 2021, then surged by 1631bps to 854.06% in 2022.
  • The last three reported values for FCF Margin were 854.06% (Q2 2022), 949.82% (Q1 2022), and 55.78% (Q4 2021) per Business Quant data.